News

21
Dec

Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government

Launch of Clinical Trials Quebec, Powered by Catalis, in Partnership With the Quebec Government   Clinical trials are an essential step in the successful development of any innovative treatment that benefits our society. Yet few people understand their importance. This is why CATALIS Quebec is proud to have coordinated the development of Clinical Trials Quebec (CTQ), a brand-new information and

Read more

10
Oct

A New Chair and a New Member of CATALIS Quebec’s Board of Directors

A New Chair and a New Member of CATALIS Quebec’s Board of Directors   Since 2017, CATALIS Quebec’s Board of Directors (BOD) has featured experts from Quebec healthcare institutions, pharmaceutical companies, and independent directors. The Board ensures the sound governance of CATALIS and of its strategic direction, in order to implement the execution of common provincial solutions that will accelerate the discovery of innovative treatments for the benefit of the province’s patients.  CATALIS is pleased to announce the appointment of Me Jean Groleau as Chair of the Board of Directors

Read more

10
Oct

First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service

First Pfizer Pharmaceutical Company Trial Authorized With a Median of 8.2 Weeks Using the FAST TRACK Evaluation Service    For the first time, the Pfizer pharmaceutical company used CATALIS’ FAST TRACK Evaluation Service to authorize a complex Phase Ia/Ib oncology clinical trial, meaning a master protocol that includes several sub-studies. In this study, Pfizer is assessing the effectiveness of a

Read more

10
Oct

The Personalized Clinical Trial Support Service Welcomes Five New Patient Associations   

The Personalized Clinical Trial Support Service Welcomes Five New Patient Associations      Clinical Trials Quebec’s Personalized Clinical Trial Support Service, the newest CATALIS initiative, is available to the following five patient associations: Sickle Cell Anemia Association of Quebec, Ovarian Cancer Canada, Save Your Skin Foundation, Parkinson Québec, and Scleroderma Quebec. These new collaborations aim to provide new patient communities and caregivers with free access to simplified and verified information about available

Read more

10
Oct

AbCellera Joins the CATALIS Network

AbCellera Joins the CATALIS Network   CATALIS is delighted to welcome AbCellera to its Network of Partners. This new pharmaceutical company will strengthen the CATALIS Network by joining the other partners: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb (BMS), GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. Together, these partners support CATALIS in its mission to optimize the

Read more

10
Oct

Provincial Reference Tools: CATALIS Contributed to the Update

Provincial Reference Tools: CATALIS Contributed to the Update    To fulfill its government mandate of optimizing Quebec’s clinical research environment and accelerating the development of innovative treatments for patients, CATALIS participated in the update of five provincial reference tools: the Standard Operating Procedures (SOPs) for Research Ethics Boards (REBs), the Statement on Optimizing the Research Contract Negotiation Process, a provincial

Read more

14
Dec

Catalis in Support of the Quebec Government’s Policy on Rare Diseases

CATALIS in Support of the Quebec Government’s Policy on Rare Diseases   On June 6, the Quebec government unveiled its Politique québécoise pour les maladies rares (Quebec policy on rare diseases – in French only). In Quebec, 700,000 people with rare diseases, half of whom are children, face significant challenges such as errors in diagnosing their disease and the absence

Read more

14
Dec

MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease

MASter-1 Study: Authorization in 8 Weeks to Explore a New Treatment for an Extremely Rare Disease   As mentioned in our December 2022 newsletter, CATALIS is proud to support the Quebec government’s Politique québécoise sur les maladies rares (Quebec policy on rare diseases – in French only), namely by allowing studies to be activated more quickly thanks to its FAST

Read more

14
Dec

STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy

STRENGTH Study: Zolgensma for Children Aged 2 to 12 With Spinal Muscular Atrophy   In October 2021, Minister Dubé announced that Zolgensma, a drug produced by the Novartis pharmaceutical company, was added to the list of drugs offered in Quebec health facilities to treat children under the age of 2 with spinal muscular atrophy. Spinal muscular atrophy is a rare

Read more

14
Dec

Astrazeneca and Vertex Join the Catalis Network

Astrazeneca and Vertex Join the Catalis Network   CATALIS Quebec is very proud to announce that pharmaceutical companies AstraZeneca and Vertex are joining the CATALIS Network. As new members, they join Abbvie, Bayer, Boehriger Ingelheim, GSK, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda. Together, the partners support CATALIS in its mission to optimize the clinical research environment to accelerate the

Read more